OUR SCIENCE

REWRITING THE BIOLOGY OF CHRONIC WOUND HEALING

WiTii Pharmaceuticals is advancing a first-in-class, mechanism driven therapeutic approach to diabetic chronic wound healing targeting the biological drivers that prevent wounds from closing. Our work is built on a simple but overlooked insight:

Healing does not fail because signals are absent—but because they cannot function.

UNDERLYING BIOLOGY OF NON-HEALING WOUNDS

Chronic diabetic wounds are characterized by a dysregulated wound environment, where key healing processes are actively impaired. A central driver of this dysfunction is elevated levels of few enzymes including Cathepsin K (CatK) that lead to:
  • Degradation of extracellular matrix (ECM)
  • Breakdown of structural support required for healing
  • Impaired cell migration and tissue regeneration
  • Disruption of signaling pathways essential for repair

This creates an environment where healing signals are present— but biologically ineffective

FIRST-IN-CLASS MECHANISM

Targeting Cathepsin K to Restore Healing

WiTii’s lead candidate represents a first-in-class therapeutic approach in chronic wound care:

  • No currently approved DFU therapies specifically target Cathepsin K or related proteases
  • Focused on a root molecular driver of persistent non-healing wounds

Mechanistic Rationale

By modulating Cathepsin K activity, our approach is designed to:

  • Stabilize the extracellular matrix
  • Preserve structural integrity of the wound environment
  • Enable effective cell migration and tissue regeneration
  • Restore conditions required for endogenous healing processes

Rather than introducing new biological signals we enable existing repair mechanisms to function as intended.

REPURPOSING WITH BIOLOGICAL PRECISION

WiTii combines deep biological insight with strategic drug repurposing:

  • Leveraging clinically studied compounds with established safety profiles
  • Applying them in novel, localized therapeutic contexts
  • Aligning known pharmacology with a new mechanistic target

Why This Matters:

By modulating Cathepsin K activity, our approach is designed to:

  • Accelerated development timelines
  • Reduced scientific and clinical risk
  • Improved capital efficiency
  • Faster path toward clinical validation

DIFFERENTIATION FROM CURRENT CARE

Most current DFU treatments focus on:

  • Growth factors
  • Advanced wound dressings
  • Skin substitutes

There are limitations of existing approaches. These therapies:

  • Do not directly address excess protease activity
  • Do not stabilize the wound microenvironment
  • Often fail to deliver consistent, durable healing outcomes

WITII'S DIFFERENTIATION

WiTii’s approach is built on addressing the underlying biological imbalance:

  • Targeting the mechanisms that actively inhibit healing
  • Restoring the environment required for repair
  • Enabling more reliable and consistent healing outcomes
Explore Our Pipeline

SCIENCE THAT TRANSLATES

WiTii’s platform integrates:

  • Validated scientific foundations
  • Mechanism-driven therapeutic design
  • Repurposed, clinically studied compounds
  • Proprietary biological insights

What It Creates:

  • A differentiated, first-in-class therapeutic strategy
  • A de-risked development pathway
  • A scalable platform with potential beyond diabetic wounds

WiTii is not developing another wound therapy:  we are restoring the biological conditions required for healing to occur.